Stock AKBA AKEBIA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Akebia Therapeutics, Inc.

Equities

AKBA

US00972D1054

Delayed Nasdaq
Other stock markets
 01:00:00 2024-07-03 pm EDT 		5-day change 1st Jan Change
0.9465 USD -1.41% Intraday chart for Akebia Therapeutics, Inc. +2.36% -23.67%
Jul. 01 Akebia Therapeutics, Inc.(NasdaqCM:AKBA) added to Russell 2500 Index CI
Jul. 01 Akebia Therapeutics, Inc.(NasdaqCM:AKBA) added to Russell 3000 Index CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Akebia Therapeutics, Inc.(NasdaqCM:AKBA) added to Russell 2500 Index
CI
Akebia Therapeutics, Inc.(NasdaqCM:AKBA) added to Russell 3000 Index
CI
Akebia Therapeutics, Inc.(NasdaqCM:AKBA) added to Russell 3000E Value Index
CI
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
PR
Akebia Therapeutics Names Erik Ostrowski CFO, CBO
MT
Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer
PR
Akebia Therapeutics, Inc. Appoints Erik Ostrowski as Senior Vice President and Chief Business Officer
CI
Akebia Therapeutics, Inc. Appoints Erik Ostrowski as Chief Financial Officer
CI
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference
PR
Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference
PR
Transcript : Akebia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
Earnings Flash (AKBA) AKEBIA THERAPEUTICS Reports Q1 Revenue $32.6M
MT
Akebia Therapeutics: Q1 Earnings Snapshot
AQ
Akebia Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
PR
Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights
PR
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AKBA Stock
  4. News Akebia Therapeutics, Inc.